Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. - Wikidata - awgldk - TriplyDB

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

http://www.wikidata.org/entity/Q37501085

about

Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation.Emerging role of precision medicine in biliary tract cancers

P2860

Q48276305-4BCD1F6A-C157-4F35-8E18-76F09C1DDC68 Q57298169-592F7DF8-4236-46F3-AC4E-80B03F1C3E6E

P2860

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

http://www.wikidata.org/entity/Q37501085

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

@en

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

@nl

type

label

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

@en

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

@nl

prefLabel

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

@en

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

@nl

P1433

Q37501085-0573CC02-B0A2-45F0-82C9-4E493184342C

P1476

Q37501085-EF6E0681-67F8-4893-A322-640D459DAF83

P2093

Q37501085-00B4A385-D734-414C-9EDD-FC0FA635FFE9

Q37501085-01D9F085-F18B-48A7-B219-0FF057D82864

Q37501085-0419DE2D-BAA2-41AC-BCCB-2CDD109680CC

Q37501085-17ADAFC2-0022-416E-93E3-DD49BC0310AA

Q37501085-1E5EDC91-D00C-4A3F-8E4C-4936DC942AC8

Q37501085-31655F8E-F01C-4787-9757-B4339900E11E

Q37501085-35BF028D-B671-4D27-B157-430FC6875565

Q37501085-88E6ED2B-0A1A-4738-85E8-E0B7F3C37C1F

Q37501085-C3DB546E-61D5-45BD-AE72-2E921D29FE02

Q37501085-D750B5A4-1143-4D90-A9D5-E840732338DF

P2860

Q37501085-0563DF1E-B845-4B17-B20D-6BCA137E4016

Q37501085-136D01BF-22FC-485E-9A9D-F07C2014F450

Q37501085-24077BAF-0C09-4618-9283-FA6F8B93AD3D

Q37501085-254D47BA-428E-485C-8A04-E8FDC6D52A4A

Q37501085-2D5A1182-5645-4EEE-91F9-201A3547B04D

Q37501085-367E22A7-711A-412F-ACAF-5D249B1F2610

Q37501085-4C8B97B5-AABA-43AE-9582-A341AF217A3B

Q37501085-676971A7-E242-4096-BE46-2CFA1BC6BB0E

Q37501085-6BFE6AB6-1452-4935-9954-CA998B5F8094

Q37501085-7AE5B2A9-6F33-45FC-A2FB-9F9B86787541

P304

Q37501085-DD0DB7C7-5A2C-47E2-857E-1AF6C8E79DE3

P31

Q37501085-31A998D6-941A-495D-B7B0-4451932F247C

Q37501085-c739c037-e199-461c-80a9-fa196abdcdf6

P356

Q37501085-12F516DF-68D1-4D6D-968A-D22E452E2215

P407

Q37501085-1F968E81-3C2A-4D08-81AE-69C8C45DD1F4

P433

Q37501085-B296C541-978B-41B1-BB8E-8ED0344C41AE

P478

Q37501085-76F5004A-5136-4BA2-9538-0ECD686EFBA8

P577

Q37501085-C5A8A536-9E54-4CD1-9CCB-18252485B4FD

P698

Q37501085-0A698CBF-968A-40F8-9AB7-D1C62F5E6C0D

P932

Q37501085-076B7D57-6DE0-4B22-81DB-5C95B3962EFD

P356

WJG.V22.I46.10254

P1433

World Journal of Gastroenterology

P1476

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

@en

P2093

An-Qiang Wang

http://www.w3.org/2001/XMLSchema#string

Da-Dong Zhang

http://www.w3.org/2001/XMLSchema#string

Fu-Gen Li

http://www.w3.org/2001/XMLSchema#string

Hai-Tao Zhao

http://www.w3.org/2001/XMLSchema#string

Jia-Jia Xu

http://www.w3.org/2001/XMLSchema#string

Kai Wang

http://www.w3.org/2001/XMLSchema#string

Xiao-Bo Yang

http://www.w3.org/2001/XMLSchema#string

Xin-Ting Sang

http://www.w3.org/2001/XMLSchema#string

Xue-Shuai Wan

http://www.w3.org/2001/XMLSchema#string

Yan Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers

BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Cancer statistics, 2014

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers

BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma

The role of BRCA1 and BRCA2 in prostate cancer.

P304

10254-10259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V22.I46.10254

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28028375

http://www.w3.org/2001/XMLSchema#string

P932

5155186

http://www.w3.org/2001/XMLSchema#string